Serological protection induced by Haemophilus influenzae type b conjugate vaccine in Mexican children: Is a booster dose of the vaccine needed?

Clinical and Vaccine Immunology

Volumn 17, Issue 10, 2010, Pages 1639-1641

  Rodriguez, Romeo S ^a   Mascarenas, Cesar ^b   Conde Glez, Carlos J ^c   Inostroza, Jaime ^d,e   Villanueva, Sonia ^d   Velázquez, María Elena ^c   Sánchez Alemán, Miguel Angel ^c   Echániz, Gabriela ^c  

^a Ministry of Health   (Mexico)

^b Sanofi Pasteur   (Mexico)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^d Hospital Regional de Temuco   (Chile)

^e UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; INFECTION PREVENTION; INFLUENZA; MEXICO; PRIORITY JOURNAL; SEROLOGY; SEROPREVALENCE;

EID: 77957874160     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00249-10     Document Type: Article

References (28)

1. Adegbola, R. A., O. Secka, G. Lahai, N. Lloyd-Evans, A. Njie, S. Usen, C. Oluwalana, S. Obaro, M. Weber, T. Corrah, K. Mulholland, K. McAdam, B. Greenwood, and P. J. Milligan. 2005. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 366:144-150.
2. Amanna, I. J., N. E. Carlson, and M. K. Slifka. 2007. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357:1903-1915.
3. Capeding, M. R., J. Cadorna-Carlos, M. Book-Montellano, and E. Ortiz. 2008. Immunogenicity and safety of a DTaP-IPV//PRP∼T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bull. World Health Organ. 86:443-451.
4. Carlsson, R. M., B. A. Claesson, U. Selstam, E. Fagerlund, M. Granstrom, C. Blondeau, and A. Hoffenbach. 1998. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr. Infect. Dis. J. 17:1026-1033.
5. Cruces, R. P., F. A. Donoso, A. J. Camacho, and H. M. Llorente. 2006. Invasive infections caused by Haemophilus influenzae type b after the institution of the conjugated vaccine on the expanded program on immunization in Chile. Rev. Chilena Infectol. 23:50-54.
6. Danovaro-Holliday, M. C., S. Garcia, C. de Quadros, G. Tambini, and J. K. Andrus. 2008. Progress in vaccination against Haemophilus influenzae type b in the Americas. PLoS Med. 5:e87.
7. Fernandez, J., S. Balter, J. Feris, E. Gomez, Z. Garib, P. L. Castellanos, J. Sanchez, S. Romero-Steiner, and O. S. Levine. 2000. Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine. Am. J. Trop. Med. Hyg. 62:485-490.
8. Fitzgerald, M., M. Canny, and D. O'Flanagan. 2005. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill. 10:E050929.
9. Franco-Paredes, C., L. Lammoglia, I. Hernandez, and J. I. Santos-Preciado. 2008. Epidemiology and outcomes of bacterial meningitis in Mexican children: 10-year experience (1993-2003). Int. J. Infect. Dis. 12:380-386.
10. Heath, P. T., and J. McVernon. 2002. The UK Hib vaccine experience. Arch. Dis. Child. 86:396-399.
11. Hviid, A., and M. Melbye. 2004. Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. Vaccine 22:378-382.
12. Kalies, H., T. Verstraeten, V. Grote, N. Meyer, A. Siedler, H. J. Schmitt, T. Breuer, L. H. Moulton, and R. von Kries. 2004. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr. Infect. Dis. J. 23:944-950. (Pubitemid 40812782)
13. Lagos, R., K. Kotloff, A. Hoffenbach, O. San Martin, P. Abrego, A. M. Ureta, E. Pines, C. Blondeau, F. Bailleux, and M. M. Levine. 1998. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr. Infect. Dis. J. 17:294-304.
14. Mallet, E., P. Fabre, E. Pines, H. Salomon, T. Staub, F. Schodel, P. Mendelman, L. Hessel, G. Chryssomalis, E. Vidor, and A. Hoffenbach. 2000. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr. Infect. Dis. J. 19:1119-1127.
15. Murphy, T. V., P. Pastor, F. Medley, M. T. Osterholm, and D. M. Granoff. 1993. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J. Pediatr. 122:517-523.
16. Murphy, T. V., K. E. White, P. Pastor, L. Gabriel, F. Medley, D. M. Granoff, and M. T. Osterholm. 1993. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA 269:246-248.
17. Olaiz-Fernandez, G., J. Rivera-Domarco, T. Shamah-Levy, R. Rojas, S. Villalpando-Hernandez, M. Hernández-Avila, and J. Sepulveda-Amor. 2006. Encuesta nacional de salud y nutrición 2006. Instituto Nacional de Salud Pública Press, Cuernavaca, Mexico.
18. Pan American Health Organization. 1996. Impact of Uruguay's introduction of the Haemophilus influenzae type b (Hib) vaccine. EPI Newsl. 18:6.
19. Peltola, H., E. Salo, and H. Saxen. 2005. Incidence of Haemophilus influenzae type b meningitis during 18 years of vaccine use: observational study using routine hospital data. BMJ 330:18-19.
20. Ramsay, M. E., J. McVernon, N. J. Andrews, P. T. Heath, and M. P. Slack. 2003. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis. 188:481-485.
21. Rentería, A. 2007. La cartilla nacional de vacunación de México para 2007. Arch. Invest. Pediatr. Mex. 10:3-4.
22. Romanin, V., L. Chiavetta, M. C. Salvay, M. J. Chiolo, M. Regueira, A. Barrios, and G. Califano. 2007. Vacuna anti-Haemophilus influenzae de tipo b (Hib) en el calendario nacional de Argentina: portación nasofaríngea de Hib tras 8 años de su introducción. Arch. Argent Pediatr. 105:498-505.
23. Schouls, L. M., A. van der Ende, I. van de Pol, C. Schot, L. Spanjaard, P. Vauterin, D. Wilderbeek, and S. Witteveen. 2005. Increase in genetic diversity of Haemophilus influenzae serotype b (Hib) strains after introduction of Hib vaccination in The Netherlands. J. Clin. Microbiol. 43:2741-2749.
24. Slack, M. H., D. Schapira, R. J. Thwaites, M. Burrage, J. Southern, D. Goldblatt, and E. Miller. 2004. Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. Arch. Dis. Child. Fetal Neonatal Ed. 89:F269-F271.
25. Spanjaard, L., S. van den Hof, H. E. de Melker, P. E. Vermeer-de Bondt, A. van der Ende, and G. T. Rijkers. 2005. Increase in the number of invasive Haemophilus influenzae type b infections. Ned. Tijdschr. Geneeskd. 149:2738-2742. (In Dutch.)
26. Takala, A. K., J. Eskola, M. Leinonen, H. Kayhty, A. Nissinen, E. Pekkanen, and P. H. Makela. 1991. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J. Infect. Dis. 164:982-986.
27. Wenger, J. D., J. DiFabio, J. M. Landaverde, O. S. Levine, and T. Gaafar. 1999. Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four "newly adopting" countries. Vaccine 18:736-742.
28. World Health Organization. 2006. WHO position paper on Haemophilus influenzae type b conjugate vaccines, p. 445-452. World Health Organization, Geneva, Switzerland.